CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...

Archery has struggled for recognition in Nigeria for decades. Now, a governance crisis threatens its very existence.

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- c/side, a cybersecurity company specializing in browser-side third-party scripts, is now available in AWS Marketplace, a digital catalog with ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.

Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. This report contains a ...

With CAR-TCR therapies on the cusp of achieving global approval, there are still many bottlenecks that are preventing this from becoming the ‘sell-out’ therapy that the field had hoped for ...